Compare CXM & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | CRVS |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2016 |
| Metric | CXM | CRVS |
|---|---|---|
| Price | $5.50 | $14.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $8.28 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 4.6M | 1.2M |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $857,200,000.00 | N/A |
| Revenue This Year | $2.52 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $60.72 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $4.72 | $3.38 |
| 52 Week High | $9.40 | $26.95 |
| Indicator | CXM | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 45.36 |
| Support Level | $5.19 | $13.81 |
| Resistance Level | $6.16 | $19.21 |
| Average True Range (ATR) | 0.23 | 1.23 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 88.35 | 12.34 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.